Logo image of KRTX

KARUNA THERAPEUTICS INC (KRTX) Stock Fundamental Analysis

NASDAQ:KRTX - Nasdaq - US48576A1007 - Common Stock - Currency: USD

329.83  +0.09 (+0.03%)

After market: 329.83 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KRTX. KRTX was compared to 572 industry peers in the Biotechnology industry. While KRTX has a great health rating, there are worries on its profitability. KRTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KRTX has reported negative net income.
KRTX had a negative operating cash flow in the past year.
In the past 5 years KRTX always reported negative net income.
KRTX had a negative operating cash flow in each of the past 5 years.
KRTX Yearly Net Income VS EBIT VS OCF VS FCFKRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M

1.2 Ratios

KRTX's Return On Assets of -32.46% is fine compared to the rest of the industry. KRTX outperforms 69.32% of its industry peers.
KRTX has a better Return On Equity (-34.58%) than 78.14% of its industry peers.
Industry RankSector Rank
ROA -32.46%
ROE -34.58%
ROIC N/A
ROA(3y)-27.82%
ROA(5y)-22.87%
ROE(3y)-29.25%
ROE(5y)-23.85%
ROIC(3y)N/A
ROIC(5y)N/A
KRTX Yearly ROA, ROE, ROICKRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRTX Yearly Profit, Operating, Gross MarginsKRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

8

2. Health

2.1 Basic Checks

KRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KRTX has been increased compared to 1 year ago.
Compared to 5 years ago, KRTX has more shares outstanding
There is no outstanding debt for KRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRTX Yearly Shares OutstandingKRTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
KRTX Yearly Total Debt VS Total AssetsKRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 90.95 indicates that KRTX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 90.95, KRTX belongs to the top of the industry, outperforming 98.81% of the companies in the same industry.
There is no outstanding debt for KRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 90.95
ROIC/WACCN/A
WACC8.97%
KRTX Yearly LT Debt VS Equity VS FCFKRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

KRTX has a Current Ratio of 19.31. This indicates that KRTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 19.31, KRTX belongs to the best of the industry, outperforming 93.56% of the companies in the same industry.
A Quick Ratio of 19.31 indicates that KRTX has no problem at all paying its short term obligations.
KRTX has a better Quick ratio (19.31) than 93.56% of its industry peers.
Industry RankSector Rank
Current Ratio 19.31
Quick Ratio 19.31
KRTX Yearly Current Assets VS Current LiabilitesKRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for KRTX have decreased strongly by -34.42% in the last year.
Looking at the last year, KRTX shows a very negative growth in Revenue. The Revenue has decreased by -93.89% in the last year.
EPS 1Y (TTM)-34.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.59%
Revenue 1Y (TTM)-93.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 32.97% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 331.85% on average over the next years. This is a very strong growth
EPS Next Y-5.2%
EPS Next 2Y13.86%
EPS Next 3Y27.79%
EPS Next 5Y32.97%
Revenue Next Year1701.02%
Revenue Next 2Y1192.99%
Revenue Next 3Y680.54%
Revenue Next 5Y331.85%

3.3 Evolution

KRTX Yearly Revenue VS EstimatesKRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
KRTX Yearly EPS VS EstimatesKRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 20 30 40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KRTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRTX Price Earnings VS Forward Price EarningsKRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRTX Per share dataKRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

A more expensive valuation may be justified as KRTX's earnings are expected to grow with 27.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.86%
EPS Next 3Y27.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KARUNA THERAPEUTICS INC

NASDAQ:KRTX (3/15/2024, 8:00:03 PM)

After market: 329.83 0 (0%)

329.83

+0.09 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-22 2024-02-22/bmo
Earnings (Next)05-02 2024-05-02/amc
Inst Owners0.38%
Inst Owner Change0%
Ins Owners7.23%
Ins Owner Change0%
Market Cap12.58B
Analysts68.7
Price Target329.12 (-0.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.15%
Min EPS beat(2)-12.95%
Max EPS beat(2)-11.34%
EPS beat(4)2
Avg EPS beat(4)-5.26%
Min EPS beat(4)-12.95%
Max EPS beat(4)2.87%
EPS beat(8)4
Avg EPS beat(8)-2.43%
EPS beat(12)7
Avg EPS beat(12)2.66%
EPS beat(16)10
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.14%
PT rev (3m)21.05%
EPS NQ rev (1m)-10.81%
EPS NQ rev (3m)-9.9%
EPS NY rev (1m)-8.48%
EPS NY rev (3m)-8.48%
Revenue NQ rev (1m)-31.35%
Revenue NQ rev (3m)-31.35%
Revenue NY rev (1m)-48.2%
Revenue NY rev (3m)-50.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19358.48
P/FCF N/A
P/OCF N/A
P/B 10.03
P/tB 10.03
EV/EBITDA N/A
EPS(TTM)-11.72
EYN/A
EPS(NY)-12.33
Fwd EYN/A
FCF(TTM)-10.19
FCFYN/A
OCF(TTM)-10.11
OCFYN/A
SpS0.02
BVpS32.88
TBVpS32.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.46%
ROE -34.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.82%
ROA(5y)-22.87%
ROE(3y)-29.25%
ROE(5y)-23.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.49%
Cap/Sales 448.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.31
Quick Ratio 19.31
Altman-Z 90.95
F-Score2
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)285.44%
Cap/Depr(5y)267.27%
Cap/Sales(3y)154.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.59%
EPS Next Y-5.2%
EPS Next 2Y13.86%
EPS Next 3Y27.79%
EPS Next 5Y32.97%
Revenue 1Y (TTM)-93.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year1701.02%
Revenue Next 2Y1192.99%
Revenue Next 3Y680.54%
Revenue Next 5Y331.85%
EBIT growth 1Y-70.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.48%
EBIT Next 3Y26.73%
EBIT Next 5Y28.98%
FCF growth 1Y-69.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.21%
OCF growth 3YN/A
OCF growth 5YN/A